GAT-1 (IC50 = 0.28 μM); GAT-2 (IC50 = 137.34 μM); GAT-3 (IC50 = 202.8 μM)

Weak antiallodynic effects are shown with SKF89976A. SKF89976A mildly inhibits the norepinephrine transporter (NET), dopamine transporter (DAT), and serotonin transporter (SERT) in Chinese hamster ovary (CHO) cells that are stable transducers of each transporter, as determined by a substrate uptake experiment. 3514, 202.13, and 728.8 are the IC50 values, respectively [1]. A GABA transmission blocker is SKF89976A. The inward current generated by GABA (1 mM) was not impacted by 100 μM picrotoxin, but it was totally suppressed by the GABA transport inhibitors tiagabine (10 μM) and SKF89976A (100 μM). It is known that 100 μM SKF 89976-A fully and reversibly blocks GABA-induced currents via blocking GABA transport into cells [2]. GAT-1 is blocked non-transferably by SKF89976A. Additionally, baseline inward currents that may result from background GABA activation of tonic GAT are inhibited by SKF89976-A. In every cell under investigation, SKF89976A (100 μM) reversibly decreased GAT current by 67.9±4.4% (n= 19). GABA-induced GAT currents were gradually decreased and inhibited by intracellular infusion of 20 μM SKF89976-A, whereas GABAAR-mediated currents (n=4) were not prevented [3].

---

Comparison of the inhibitory potency of GAT inhibitors To analyze the effects of GAT inhibitors on the uptake of [3 H]GABA, we previously established cell lines stably expressing GAT subtypes using CHO cells. Using these cell lines together with CHO cells stably expressing rat monoamine transporters SERT, NET, and DAT to compare the potencies in inhibiting GAT subtypes, we analyzed the effect of GAT inhibitors on the uptake of GABA and monoamines. The inhibitors SKF89976A and (S)-SNAP5114 exhibited subtype selectivity for GAT-1 (IC50: 0.28 mM) and GAT-3 (IC50: 5.31 mM), respectively (Table 1). However, NNC05-2090 potently inhibited GAT-1 (IC50: 29.62 mM), with IC50 values more than 2.5-fold lower being observed for BGT-1 (10.60 mM). NNC05-2090 also showed markedly higher IC50 values for GAT-2 (45.29 mM) and GAT-3 (22.51 mM). These results indicate that of all the GAT inhibitors examined, NNC05-2090 has highest potency inhibiting BGT-1 between GAT inhibitors. NNC05-2090 also inhibited SERT, NET, and DAT (IC50: 5.29 mM, 7.91 mM, and 4.08 mM, respectively), and these IC50 values were similar to that for BGT-1 [1].

---

Although glial GABA uptake and release have been studied in vitro, GABA transporters (GATs) have not been characterized in glia in slices. Whole cell patch-clamp recordings were obtained from Bergmann glia in rat cerebellar slices to characterize carrier-mediated GABA influx and efflux. GABA induced inward currents at -70 mV that could be pharmacologically separated into GABA(A) receptor and GAT currents. In the presence of GABA(A/B/C) receptor blockers, mean GABA-induced currents measured -48 pA at -70 mV, were inwardly rectifying between -70 and +50 mV, were inhibited by external Na(+) removal, and were diminished by reduction of external Cl(-). Nontransportable blockers of GAT-1 (SKF89976A and NNC-711) and a transportable blocker of all the GAT subtypes (nipecotic acid) reversibly reduced GABA-induced transport currents by 68 and 100%, respectively. A blocker of BGT-1 (betaine) had no effect. SKF89976-A and NNC-711 also suppressed baseline inward currents that likely result from tonic GAT activation by background GABA. The substrate agonists, nipecotic acid and beta-alanine but not betaine, induced voltage- and Na(+)-dependent currents. With Na(+) and GABA inside the patch pipette or intracellular GABA perfusion during the recording, SKF89976A blocked baseline outward currents that activated at -60 mV and increased with more depolarized potentials. This carrier-mediated GABA efflux induced a local accumulation of extracellular GABA detected by GABA(A) receptor activation on the recorded cell. Overall, these results indicate that Bergmann glia express GAT-1 that are activated by ambient GABA. In addition, GAT-1 in glia can work in reverse and release sufficient GABA to activate nearby GABA receptors [3].

SKF89976A given intravenously (0.3 mg/kg) elicits a mild antiallodynic effect. In PSL model mice, injection of SKF89976A can improve the decrease of withdrawal threshold in a dose-dependent manner [1].

---

Effects of GAT inhibitors on mechanical allodynia in a mouse model of PSL The mechanical withdrawal threshold was significantly lower on the ipsilateral side in partial sciatic nerve ligation (PSL) model mice than in sham-operated animals (Fig. 1). A reduction was not observed in the mechanical withdrawal threshold on the contralateral side (Figs. 2B, 3B, 4, and 5). Mechanical allodynia in the mouse model of PSL was not affected by the saline treatments (Fig. 1B). An increase was observed in the mechanical withdrawal threshold in PSL model mice 3 h after the administration i.p. of 0.1 mg/kg NNC05-2090 (Fig. 1B). On the other hand, a 0.3 mg/kg, i.p. injection of SKF89976A did not induce any significant effect on the withdrawal threshold in PSL model mice (Fig. 1B). Intravenous (i.v.) injection of the BGT-1 inhibitor NNC05-2090 significantly reversed mechanical allodynia in PSL model mice (Fig. 2). A dose-dependent response to NNC05-2090 was shown in the range of 0.01 – 0.1 mg/kg by an i.v. injection. i.t. injection of the BGT-1 inhibitor NNC05-2090 also significantly reversed mechanical allodynia in PSL model mice, and a dosedependent response to NNC05-2090 was also shown in the range of 15 – 150 pmoles by an i.t. injection to PSL model mice (Fig. 3). Antiallodynic effects peaked within 1 h after the injection of NNC05-2090, with the exception of the 0.01 mg/kg, i.v. administration (Figs. 2 and 3). No significant difference was observed in the withdrawal threshold on the contralateral side after the administration of NNC05-2090. SKF89976A produced a weak antiallodynic response when administered i.v. (0.3 mg/kg) (Fig. 4A). As is shown in Fig. 5A, the i.t. injection of SKF89976A dose-dependently ameliorated the reduction in the withdrawal threshold in PSL model mice. We also injected the GAT-3 inhibitor (S)-SNAP5114 to examine its antiallodynic effect on mechanical allodynia in PSL mice. Neither the i.v. nor i.t. injection of (S)-SNAP5114 had a significant effect on the reduction in the withdrawal threshold in PSL model mice (Fig. 4B and 5B) [1].

INTRACELLULAR PERFUSION OF A GABA TRANSPORTER BLOCKER DURING THE RECORDING.[3]
Intracellular perfusion of a GABA transporter blocker was performed as previously reported by others for single or multiple drugs application (Tang et al. 1990). We used a straight pipette holder with a perfusion port (EH-U2, E. W. Wright). Through the perfusion port, a polyethylene tube (0.86 mm ID and 1.27 mm OD) was introduced sufficiently far to reach well into the patch pipette solution. A 1-ml syringe containing the LY-filled intracellular solution to be perfused during the recording was connected to the polyethylene tube via an elongated and thinned plastic pipette tip. Before adding the patch pipette, positive pressure was manually applied to fill up the tube all away to the end, remove air bubbles, and visualize efflux of solution. Then, after applying negative pressure to prevent any solution leakage but without adding an air bubble to the end of the tube, the patch pipette was inserted into the holder. To perfuse the LY-filled solution containing either GABA or SKF89976A, a positive pressure was manually applied to add sufficient solution to double the volume in the patch pipette (about 20 μl). The concentrations of GABA and SKF89976A were double to obtain the intended final concentrations in the cell.

Drug preparation and administration [1]
Animals were used in experiments approximately 2 weeks (11 – 16 days) following nerve ligation. Animals were administered NNC05-2090, SKF89976A, (S)- SNAP5114, or amitriptyline. NNC05-2090, SKF89976A, and (S)-SNAP5114 were dissolved in dimethyl sulfoxide (DMSO) and diluted appropriately with ACSF or saline (the final concentration of DMSO was less than 0.5%). The composition of ACSF (in mM) was 142 mM NaCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 1.25 mM NaH2PO4, 10 mM d-glucose, 10 mM HEPES, and 0.05% fatty acid-free bovine serum albumin (pH 7.4). The intraperitoneal (i.p.) injection of drugs was administered in a volume of 0.1 ml/10 g body weight. When given intravenously (i.v.), solutions were injected into the tail vein in a volume of 0.1 ml/10 g body weight. The head of a mouse was placed into a plastic cap and the body was held with one hand for an intrathecal (i.t.) injection. A 27-gauge needle attached to a Hamilton microsyringe was inserted into the subarachnoid space between the L5 and L6 vertebrae of the conscious mouse and 5 ml of the drug solution was slowly injected, as described by Hylden and Wilcox (31). Accurate placement of the needle was confirmed by a quick “flick” of the mouse’s tail, as described by Honda et al.

[1]. Antiallodynic action of 1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(2-methyoxyphenyl)-4-piperidinol (NNC05-2090), a betaine/GABA transporter inhibitor. J Pharmacol Sci. 2014;125(2):217-26.

[2]. Glutamate modulation of GABA transport in retinal horizontal cells of the skate. J Physiol. 2003 Feb 1;546(Pt 3):717-31.

[3]. GAT-1 and reversible GABA transport in Bergmann glia in slices. J Neurophysiol. 2002 Sep;88(3):1407-19.

1-(4,4-diphenylbut-3-enyl)-3-piperidinecarboxylic acid is a diarylmethane.

---

The GABAergic system in the spinal cord has been shown to participate in neuropathic pain in various animal models. GABA transporters (GATs) play a role in controlling the synaptic clearance of GABA; however, their role in neuropathic pain remains unclear. In the present study, we compared the betaine/GABA transporter (BGT-1) with other GAT subtypes to determine its participation in neuropathic pain using a mouse model of sciatic nerve ligation. 1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(2-methyoxyphenyl)-4-piperidinol (NNC05-2090), an inhibitor that displays moderate selectivity for BGT-1, had an antiallodynic action on model mice treated through both intrathecally and intravenous administration routes. On the other hand, SKF89976A, a selective GAT-1 inhibitor, had a weak antiallodynic action, and (S)-SNAP5114, an inhibitor that displays selectivity for GAT-3, had no antiallodynic action. Systemic analysis of these compounds on GABA uptake in CHO cells stably expressing BGT-1 revealed that NNC05-2090 not only inhibited BGT-1, but also serotonin, noradrenaline, and dopamine transporters, using a substrate uptake assay in CHO cells stably expressing each transporter, with IC50: 5.29, 7.91, and 4.08 μM, respectively. These values were similar to the IC50 value at BGT-1 (10.6 μM). These results suggest that the antiallodynic action of NNC05-2090 is due to the inhibition of both BGT-1 and monoamine transporters.[1]

---

Transport of the amino acid GABA into neurons and glia plays a key role in regulating the effects of GABA in the vertebrate retina. We have examined the modulation of GABA-elicited transport currents of retinal horizontal cells by glutamate, the likely neurotransmitter of vertebrate photoreceptors. Enzymatically isolated external horizontal cells of skate were examined using whole-cell voltage-clamp techniques. GABA (1 mM ) elicited an inward current that was completely suppressed by the GABA transport inhibitors tiagabine (10 microM) and SKF89976A (100 microM), but was unaffected by 100 microM picrotoxin. Prior application of 100 microM glutamate significantly reduced the GABA-elicited current. Glutamate depressed the GABA dose-response curve without shifting the curve laterally or altering the voltage dependence of the current. The ionotropic glutamate receptor agonists kainate and AMPA also reduced the GABA-elicited current, and the effects of glutamate and kainate were abolished by the ionotropic glutamate receptor antagonist 6-cyano-7-nitroquinoxaline. NMDA neither elicited a current nor modified the GABA-induced current, and metabotropic glutamate analogues were also without effect. Inhibition of the GABA-elicited current by glutamate and kainate was reduced when extracellular calcium was removed and when recording pipettes contained high concentrations of the calcium chelator BAPTA. Caffeine (5 mM) and thapsigargin (2 nM), agents known to alter intracellular calcium levels, also reduced the GABA-elicited current, but increases in calcium induced by depolarization alone did not. Our data suggest that glutamate regulates GABA transport in retinal horizontal cells through a calcium-dependent process, and imply a close physical relationship between calcium-permeable glutamate receptors and GABA transporters in these cells.[2]

C22H26CLNO2

371.9

335.189

C, 71.05; H, 7.05; Cl, 9.53; N, 3.77; O, 8.60

85375-85-5

85375-15-1 ( free base);85375-85-5 (HCl);

92409

Light yellow to khaki Solid powder

1.121g/cm3

531.4ºC at 760 mmHg

275.2ºC

1.587

4.242

1

3

6

25

427

0

C1(/C(/C2C=CC=CC=2)=C/CCN2CCCC(C(O)=O)C2)C=CC=CC=1

SNGGBKYQZVAQKA-UHFFFAOYSA-N

InChI=1S/C22H25NO2.ClH/c24-22(25)20-13-7-15-23(17-20)16-8-14-21(18-9-3-1-4-10-18)19-11-5-2-6-12-19;/h1-6,9-12,14,20H,7-8,13,15-17H2,(H,24,25);1H

1-(4,4-diphenylbut-3-en-1-yl)piperidine-3-carboxylic acid hydrochloride

SKF89976A HCl; 85375-15-1; 1-(4,4-Diphenylbut-3-en-1-yl)piperidine-3-carboxylic acid hydrochloride; SKF 89976A hydrochloride; SKF-89,976A; ...; SKF89976-A (hydrochloride); SKF 89976A; SKF-89976A; SKF89976A hydrochloride

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)